Melanoma Clinical Trial
Official title:
A Phase I/IIa, Open-Label Bridging Safety and Pharmacodynamic Study of a New Formulation of 6 Month Extended Dosing With AGI - 101H Vaccine in the Treatment of Patients With Advanced Melanoma
In this open-label study of patients with advanced melanoma 20 evaluable patients will be
recruited.
The drug substance, AGI-101H, is a whole cell, allogeneic melanoma vaccine, representing a
mixture (1:1 ratio) of two therapeutic gene modified human melanoma cell lines, referred to
as Mich1H6 and Mich2H6, which has been gamma-irradiated to render the cells
non-proliferative
Patients will receive treatment for up to 26 weeks. Progression at any time point requiring
systemic treatment with, for example with chemotherapy or cytokines will lead to withdrawal
of this patient from the study.
The dose chosen is 5 x 107 viable cells/dose.
Total number of patients: 20 evaluable patients will be enrolled in the study.
Dosage: 5 x 107 live cells. No dose modification is planned.
Administration: Subcutaneous (s.c.)
Duration of treatment: Patients will receive treatment for up to 26 weeks. Progression at
any time point requiring systemic treatment with, for example with chemotherapy or cytokines
will lead to withdrawal of this patient from the study. All surviving patients of this
AGITAM trial will be offered the opportunity to transfer to a follow-up treatment protocol
with AGI - 101H. In this case treatment may continue every 4 - 8 weeks until progression or
death or withdrawal unless such therapy is contraindicated or patient does not wish to
continue.
Reference therapy: Not applicable.
Description of medicinal product: The drug substance, AGI-101H, is a whole cell, allogeneic
melanoma vaccine, representing a mixture (1:1 ratio) of two therapeutic genemodified human
melanoma cell lines, referred to as Mich1H6 and Mich2H6, which has been gamma-irradiated to
render the cells non-proliferative. There is no recommended International Non-proprietary
(INN) Name for the drug substance.
Methodology: In this open-label study of patients with advanced melanoma, one dose of AGI -
101H vaccine will be administered s.c.. 20 evaluable patients will be recruited. An
independent data monitoring committee (DMC) will review all safety data after the first 10
injections and then after another 10 injections (20 injections in total). Up to that second
DMC meeting all patients have to stay in the hospital for a 2 hours observation; after the
analysis of the 20 vaccinations the DMC will review the safety data and may recommend
reverting to normal outpatients setting.
;
Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05094804 -
A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents
|
Phase 1/Phase 2 | |
| Completed |
NCT03979872 -
Risk Information and Skin-cancer Education for Undergraduate Prevention
|
N/A | |
| Recruiting |
NCT04986748 -
Using QPOP to Predict Treatment for Sarcomas and Melanomas
|
||
| Enrolling by invitation |
NCT00068003 -
Harvesting Cells for Experimental Cancer Treatments
|
||
| Recruiting |
NCT05707286 -
Pilot Study to Determine Pro-Inflammatory Cytokine Kinetics During Immune Checkpoint Inhibitor Therapy
|
||
| Active, not recruiting |
NCT05470283 -
Phase I, Open-Label, Study of Tumor Infiltrating Lymphocytes Engineered With Membrane Bound IL15 Plus Acetazolamide in Adult Patients With Metastatic Melanoma
|
Phase 1 | |
| Recruiting |
NCT05077137 -
A Feasibility Study Utilizing Immune Recall to Increase Response to Checkpoint Therapy
|
Phase 1 | |
| Active, not recruiting |
NCT02721459 -
XL888 + Vemurafenib + Cobimetinib for Unresectable BRAF Mutated Stage III/IV Melanoma
|
Phase 1 | |
| Completed |
NCT00341939 -
Retrospective Analysis of a Drug-Metabolizing Genotype in Cancer Patients and Correlation With Pharmacokinetic and Pharmacodynamics Data
|
||
| Recruiting |
NCT05839912 -
Excision of Lymph Node Trial (EXCILYNT) (Mel69)
|
N/A | |
| Recruiting |
NCT04971499 -
A Study of Dapansutrile Plus Pembrolizumab in Patients With PD-1 Refractory Advanced Melanoma
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05263453 -
HL-085+Vemurafenib to Treat Advanced Melanoma Patients With BRAF V600E/K Mutation
|
Phase 2 | |
| Active, not recruiting |
NCT05060432 -
Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
| Not yet recruiting |
NCT06413680 -
A First-In Human (FIH) Trial to Find Out if REGN10597 is Safe and How Well it Works for Adult Participants With Advanced Solid Organ Malignancies
|
Phase 1/Phase 2 | |
| Completed |
NCT03348891 -
TNF in Melanoma Patients Treated With Immunotherapy
|
N/A | |
| Terminated |
NCT03399448 -
NY-ESO-1-redirected CRISPR (TCRendo and PD1) Edited T Cells (NYCE T Cells)
|
Phase 1 | |
| Completed |
NCT03171064 -
Exercise as a Supportive Measure for Patients Undergoing Checkpoint-inhibitor Treatment
|
Phase 2 | |
| Not yet recruiting |
NCT05539118 -
Interferon-α1b Combined With Toripalimab and Anlotinib Hydrochloride in Advanced Unresectable Melanoma
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05171374 -
pRospective Evaluation of Clinical Outcomes in Patients With metAsTatIс melanOma Treated With dabrafeNib and trAmetinib in reaL practicE
|
||
| Withdrawn |
NCT02854488 -
Yervoy Pregnancy Surveillance Study
|